

April 29, 2019

James Kasinger  
General Counsel and Secretary  
CRISPR Therapeutics AG  
Baarerstrasse 14  
6300 Zug  
Switzerland

Re: CRISPR Therapeutics AG  
Revised Preliminary Proxy Statement on Schedule 14A  
Filed on April 29, 2019  
File No. 001-37923

Dear Mr. Kasinger:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of

Corporation Finance

Office of Healthcare

& Insurance

cc: Robert E. Puopolo, Esq.